methylprednisolone sodium succinate

P3, N=50, Active, not recruiting, The Hospital for Sick Children | Recruiting --> Active, not recruiting | Trial completion date: Nov 2026 --> Feb 2027

P3, N=540, Recruiting, University of Sydney | Not yet recruiting --> Recruiting

P2, N=400, Recruiting, University of Birmingham | Trial completion date: Jan 2026 --> Aug 2027 | Trial primary completion date: Jan 2026 --> Aug 2027

High-dose intravenous methylprednisolone followed by tapering oral prednisone, plasma exchange (PE), and intravenous immunoglobulin (IVIG) and rituximab led to marked neurological improvement...Symptoms improved substantially with prednisone and tacrolimus, and subsequent thymectomy combined with efgartigimod further achieved sustained clinical remission...Comprehensive antibody profiling is essential for early recognition and targeted immunotherapy. Long-term immunosuppression combined with tumor-directed treatment may be required to prevent relapses of both disorders and achieve optimal clinical outcomes.

P2, N=150, Recruiting, Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea | Active, not recruiting --> Recruiting

She initially presented with grade 3 systemic CRS during step-up dosing phase, which partially resolved with intravenous methylprednisolone. At two months, the patient achieved a partial response and continued teclistamab therapy. To our knowledge, this is among the first reported cases of teclistamab-associated localized pleural cavity CRS effectively managed with intrapleural dexamethasone.

P2, N=20, Recruiting, Assistance Publique - Hôpitaux de Paris | Not yet recruiting --> Recruiting | Trial completion date: Nov 2027 --> Mar 2028 | Trial primary completion date: Nov 2026 --> May 2027

P3, N=992, The Second Affiliated Hospital of the Army Medical University; The Second Affiliated Hospital of the Army Medical University

P=N/A, N=66, Recruiting, West China Hospital of Sichuan University; West China Hospital of Sichuan University | Not yet recruiting --> Recruiting

The immune mechanism of its occurrence is still unclear and needs to be further studied. Traditional glucocorticoid is still the first-line drug, but the new targeted drug Efgartigimod has less adverse reactions and faster onset of action, which may become a good choice, but needs to be verified by a larger sample.

P3, N=3208, Completed, Children's Hospital of Fudan University | Active, not recruiting --> Completed

Immediate discontinuation of almonertinib combined with intravenous methylprednisolone resulted in significant clinical and radiological improvement within 7 days. This case highlights two important clinical implications: (1) almonertinib-associated ILD can rapidly progress to a life-threatening condition and (2) occupational inhalational exposures (e.g., dust and smoking) have been directly and indirectly implicated as potential risk factors for EGFR-TKI-induced pulmonary toxicity in prior studies and may have contributed to the outcome in this case. Clinicians should maintain heightened vigilance for respiratory complications during almonertinib therapy, particularly in patients with preexisting pulmonary risk factors.